Ned is a senior editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from the College at Georgetown University. Hoya Saxa.
1395 articles by Ned Pagliarulo
-
Novartis gene therapy approved, but will come at cost of more than $2 million
May 24, 2019 -
Nektar forms new biotech to sell under-review pain drug
May 24, 2019 -
Dynavax cuts staff in retreat from cancer research
May 24, 2019 -
Novartis looking earlier for deals as biotech valuations stay high
May 23, 2019 -
Verily lures major pharmas with promise of speedier clinical research
May 21, 2019 -
ICER seeks to make drug price research more accessible
May 20, 2019 -
Gilead CEO pressured on PrEP pricing at House hearing
May 17, 2019 -
FDA schedules Aimmune's peanut allergy drug for September expert review
May 16, 2019 -
Biotech in the spotlight at ASCO as pharma takes back seat
May 16, 2019 -
Vertex follows pharma lead in bet on protein degradation
May 15, 2019 -
Myovant reports a Phase 3 success, but Wall Street isn't cheered
May 14, 2019 -
Pharma, late to digital game, rushes to catch up
May 13, 2019 -
Catalent, hindered by Softgel weakness, sees stronger growth ahead
May 9, 2019 -
Nearing gene therapy launch, Bluebird cautions a slower start
May 9, 2019 -
Drugmakers will soon be required to disclose prices in TV ads
May 8, 2019 -
AstraZeneca blood cancer drug hits study goal early
May 7, 2019 -
'Pathbreaking' Ionis trial offers way forward in Huntington's disease
May 6, 2019 -
Trelegy success gives GSK some respiratory respite
May 3, 2019 -
Renewable energy to power all Novo drug production by next year
May 2, 2019 -
Alnylam posts strong Onpattro sales as competition heats up
May 2, 2019 -
Longtime Gilead finance chief Robin Washington to step down next year
May 1, 2019 -
At gene therapy meeting, insurance execs grapple with expected cost
April 30, 2019 -
Keytruda powers Merck to another strong quarter
April 30, 2019 -
Praluent scores heart label, matching Amgen's rival Repatha
April 29, 2019 -
Cancer drugs lift AstraZeneca, aiding turnaround
April 26, 2019